Repeated administration of a mutant cocaine esterase: Effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 205-213

  Collins, Gregory T ^a,c   Brim, Remy L ^a,d   Noon, Kathleen R ^a,e   Narasimhan, Diwahar ^a,b   Lukacs, Nicholas W ^a   Sunahara, Roger K ^a   Woods, James H ^a   Ko, Mei Chuan ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MCLEAN HOSPITAL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; COCAINE; DOUBLE MUTANT COCAINE ESTERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR EFFECT; COCAINE BLOOD LEVEL; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART RATE; HYDROLYSIS; HYPERTENSION; HYPERTHERMIA; IMMUNE RESPONSE; LIMIT OF DETECTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; RHESUS MONKEY; TACHYCARDIA;

ANIMALS; ANTIBODY FORMATION; BLOOD PRESSURE; BODY TEMPERATURE; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR SYSTEM; COCAINE; FEMALE; HEART RATE; HYDROLYSIS; MACACA MULATTA; MALE; MOTOR ACTIVITY;

EID: 84862489751     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194639     Document Type: Article

References (49)

1. Blaho K, Logan B, Winbery S, Park L, and Schwilke E (2000) Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med 18:593-598.
2. Bresler MM, Rosser SJ, Basran A, and Bruce NC (2000) Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66:904-908. (Pubitemid 30130004)
3. Brim RL, Nance MR, Youngstrom DW, Narasimhan D, Zhan CG, Tesmer JJ, Sunahara RK, and Woods JH (2010) A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol 77:593-600.
4. Brim RL, Noon KR, Collins GT, Nichols J, Narasimhan D, Sunahara RK, and Woods JH (2011a) The ability of bacterial cocaine esterase to hydrolyze cocaine metabolites and their simultaneous quantification using high-performance liquid chromatography-tandem mass spectrometry. Mol Pharmacol 80:1119-1127.
5. Brim RL, Noon KR, Collins GT, Stein A, Nichols J, Narasimhan D, Ko MC, Woods JH, and Sunahara RK (2012) The fate of bacterial cocaine esterase (CocE): an in vivo study of CocE-mediated cocaine hydrolysis, CocE pharmacokinetics, and CocE elimination. J Pharmacol Exp Ther 340:83-95.
6. Brim RL, Noon KR, Nichols J, Narasimhan D, Woods JH, and Sunahara RK (2011b) Evaluation of the hydrolytic activity of a long-acting mutant bacterial cocaine in the presence of commonly co-administered drugs. Drug Alcohol Depend 119:224-228.
7. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, and Carroll ME (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33:2715-2725.
8. Brody SL, Slovis CM, and Wrenn KD (1990) Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 88:325-331. (Pubitemid 20147265)
9. Carroll ME, Gao Y, Brimijoin S, and Anker JJ (2011) Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl) 213:817-829.
10. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, Zhan CG, and Woods JH (2009) Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther 331:445-455.
11. Collins GT, Carey KA, Narasimhan D, Nichols J, Berlin AA, Lukacs NW, Sunahara RK, Woods JH, and Ko MC (2011a) Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology 36:1047-1059.
12. Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, Ko MC, Sunahara RK, and Woods JH (2012) Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology 37:1092-1103.
13. Collins GT, Zaks ME, Cunningham AR, St Clair C, Nichols J, Narasimhan D, Ko MC, Sunahara RK, and Woods JH (2011b) Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend 118:158-165.
14. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, and Woods JH (2006) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70:1885-1891. (Pubitemid 44771904)
15. Dackis C and O'Brien C (2003) Glutamatergic agents for cocaine dependence. Ann NY Acad Sci 1003:328-345. (Pubitemid 38083066)
16. Finkle BS and McCloskey KL (1978) The forensic toxicology of cocaine (1971-1976). J Forensic Sci 23:173-189. (Pubitemid 8275298)
17. Foltin RW and Fischman MW (1991) Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 257:247-261.
18. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, and Zhan CG (2009) Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75:318-323.
19. Glauser J and Queen JR (2007) An overview of non-cardiac cocaine toxicity. J Emerg Med 32:181-186. (Pubitemid 46329303)
20. Grabowski J, Shearer J, Merrill J, and Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439-1464. (Pubitemid 39172183)
21. Hollander JE (1995) The management of cocaine-associated myocardial ischemia. N Engl J Med 333:1267-1272.
22. Hollander JE and Henry TD (2006) Evaluation and management of the patient who has cocaine-associated chest pain. Cardiol Clin 24:103-114. (Pubitemid 41745069)
23. Hollander JE, Hoffman RS, Gennis P, Fairweather P, Feldman JA, Fish SS, DiSano MJ, Schumb DA, and Dyer S (1995) Cocaine-associated chest pain: one-year follow-up. Acad Emerg Med 2:179-184.
24. Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Côté M, Herskovits P, et al. (2007) Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A 104:13603-13608. (Pubitemid 350010655)
25. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
26. Javaid JI, Fischman MW, Schuster CR, Dekirmenjian H, and Davis JM (1978) Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science 202:227-228. (Pubitemid 9055122)
27. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, and Woods JH (2009) A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med 54:409-420.
28. Karch SB, Stephens B, and Ho CH (1998) Relating cocaine blood concentrations to toxicity-an autopsy study of 99 cases. J Forensic Sci 43:41-45. (Pubitemid 28063703)
29. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper ZD, and Woods JH (2007) Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther 320:926-933. (Pubitemid 46147977)
30. Ko MC, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, and Woods JH (2009) Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend 101:202-209.
31. Koehler SA, Ladham S, Rozin L, Shakir A, Omalu B, Dominick J, and Wecht CH (2005) The risk of body packing: a case of a fatal cocaine overdose. Forensic Sci Int 151:81-84. (Pubitemid 40797663)
32. Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, and Wilson IA (2002) Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 9:17-21. (Pubitemid 34049173)
33. Malyala P and Singh M (2008) Endotoxin limits in formulations for preclinical research. J Pharm Sci 97:2041-2044.
34. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, Gibler WB, Ohman EM, Drew B, Philippides G, et al. (2008) Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 117:1897-1907. (Pubitemid 351507480)
35. Mello NK, Bowen CA, and Mendelson JH (2002) Comparison of plasma cocaine levels during a "binge" pattern of cocaine administration in male and female rhesus monkeys. Psychopharmacology (Berl) 164:19-26. (Pubitemid 35203838)
36. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Kaufman MJ, Levin JM, Renshaw PF, and Cohen BM (1999) Cocaine pharmacokinetics in men and in women during the follicular and luteal phases of the menstrual cycle. Neuropsychopharmacology 21:294-303. (Pubitemid 29304589)
37. Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, and Muller JE (1999) Triggering of myocardial infarction by cocaine. Circulation 99:2737-2741. (Pubitemid 29250018)
38. Narasimhan D, Collins GT, Nance MR, Nichols J, Edwald E, Chan J, Ko MC, Woods JH, Tesmer JJ, and Sunahara RK (2011) Subunit stabilization and polyethylene glycolation of cocaine esterase improves in vivo residence time. Mol Pharmacol 80:1056-1065.
39. Narasimhan D, Nance MR, Gao D, Ko MC, Macdonald J, Tamburi P, Yoon D, Landry DM, Woods JH, Zhan CG, et al. (2010) Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel 23:537-547.
40. Olson KR, Kearney TE, Dyer JE, Benowitz NL, and Blanc PD. (1994) Seizures associated with poisoning and drug overdose. Am J Emerg Med 12:392-395.
41. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, and Zhan CG (2005) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A 102:16656-16661. (Pubitemid 41688832)
42. Substance Abuse and Mental Health Services Administration (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication SMA-11-4658. Substance Abuse and Mental Health Services Administration, Rockville, MD.
43. Tanda G, Newman AH, and Katz JL (2009) Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57:253-289.
44. Turner JM, Larsen NA, Basran A, Barbas CF 3rd, Bruce NC, Wilson IA, and Lerner RA (2002) Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41:12297-12307.
45. United Nations Office on Drugs and Crime (2010) World Drug Report 2010. United Nations Publication E.10.XI.13, United Nations, New York.
46. Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 162:1432-1440. (Pubitemid 41105557)
47. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, and Woods JH (2010) Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend 106:219-229.
48. Xue L, Ko MC, Tong M, Yang W, Hou S, Fang L, Liu J, Zheng F, Woods JH, Tai HH, et al. (2011) Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol 79:290-297.
49. Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH, and Zhan CG (2008) Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130:12148-12155.